logo
Tecnológico de Monterrey Launches International Call for IFE Conference 2026

Tecnológico de Monterrey Launches International Call for IFE Conference 2026

Yahooa day ago

The call is open through June 15 in four categories: research papers, innovation papers, book presentations, and educational innovation case studies.
Selected submissions may be published in Springer's Lecture Notes in Educational Technology series, indexed in Scopus.
Since its creation in 2006, the IFE Conference has brought together more than 34,000 participants from over 40 countries.
MONTERREY, Mexico, June 05, 2025 (GLOBE NEWSWIRE) -- In a pivotal moment for global education, Tecnológico de Monterrey has launched a call directed at researchers, academics, and education professionals to participate as speakers in the upcoming edition of IFE Conference 2026, which will take place from January 27 to 29, 2026, in Monterrey, Mexico.
In the face of rapid advances in artificial intelligence, hybrid learning, and evolving labor market demands, teaching methods, the role of educational institutions, and lifelong learning models are undergoing a profound transformation.
Against this backdrop, the IFE Conference, organized by the Institute for the Future of Education at Tecnológico de Monterrey, aims to be a space for interdisciplinary collaboration where ideas, experiences, and solutions are shared to address the challenges of 21st-century learning. This annual summit, which since its launch in 2006 has gathered more than 34,000 participants from over 40 countries, promotes the exchange of proposals to transform education.
Four participation categories:
Research papers
Innovation papers
Book presentations
Educational innovation case studies
Proposals will be evaluated based on their relevance and originality. Research papers that meet editorial standards may be published in Springer's Lecture Notes in Educational Technology series, indexed in Scopus.
Thematic axes for the 2026 edition
The thematic focus for this edition includes five key areas
Educational trends, such as the evolution of teaching methods and the development of socioemotional skills
Educational technologies, related to the use of digital tools to enhance teaching and learning
Academic innovation in health, focused on improving medical training and research
Educational innovation management, with evaluation strategies and institutional development
Lifelong learning, aimed at building competencies for employability and personal growth
The call for proposals will remain open through June 15, 2025. Interested participants can find more information and submit their proposals through the official website: https://ifeconference.tec.mx.
Visit Tecnológico de Monterrey's Press CenterFacebook: X: Instagram: Tecnológico de Monterrey (http://www.tec.mx) is a private, non-profit university recognized for its academic excellence, educational innovation, and global vision. Founded in 1943, it operates in 33 cities across 20 states in Mexico, with an enrollment of 60,000 undergraduate and graduate students, as well as more than 27,000 high school students. Accredited by SACSCOC since 1950, Tec ranks #185 in the QS World University Rankings 2025 and #7 in Latin America according to the THE Latin America University Rankings 2024. It is also recognized for global employability and entrepreneurship programs and is a member of international networks such as APRU and U21. For more details, visit our Boilerplate: https://tec.rs/Boilerplate
CONTACT: Press Contacts: Tecnológico de Monterrey Christian Morales Cel: 55 8014 6427 Email: christianm@tec.mxSign in to access your portfolio

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AI Insider Blows the Lid Off Musk's Secret AI Operation
AI Insider Blows the Lid Off Musk's Secret AI Operation

Yahoo

time8 hours ago

  • Yahoo

AI Insider Blows the Lid Off Musk's Secret AI Operation

BALTIMORE, June 06, 2025 (GLOBE NEWSWIRE) -- A mysterious AI complex in Memphis is now being called the most powerful system of its kind — and it wasn't supposed to be public knowledge. In a newly released briefing, bestselling author and tech expert James Altucher reveals the details of a covert AI operation led by Elon Musk that, until now, has gone almost entirely unreported. Known as Project Colossus, the facility was built by Musk's AI company, xAI, and is allegedly housing the highest-density AI computing power in the Western Hemisphere. 'The AI Mothership' Altucher says the project has quietly surpassed every major tech firm in the race for AI dominance — including OpenAI, Microsoft, Meta, and even Nvidia. 'Elon Musk has created the AI mothership… an innovation of such enormous proportion… that he has already surpassed all the leading AI developers.' He adds that the complex is powered by 200,000 high-performance AI chips — and growing. 'Making it the most advanced AI facility known to man.' Buried in a Warehouse. Unleashed by Policy. According to Altucher, the project only became possible after a specific presidential action early in Trump's second term. 'In one of his FIRST acts as President… Donald Trump overturned Executive Order #14110.' That order had previously restricted advanced AI development in the name of safety and oversight. Its removal, Altucher says, opened the floodgates. Not a Tool. A Turning Point. Altucher warns that this isn't just about AI doing tasks faster. This is a leap into self-operating systems that think, react, and solve. 'AI 2.0… gives that knowledge to intelligent machines that I believe will solve our problems for us.' He claims a major update to Colossus — scheduled before July 1 — could mark the moment America enters a new technological era. About James Altucher James Altucher is a computer scientist, entrepreneur, and bestselling author with four decades of experience in artificial intelligence and innovation. His past work includes contributions to IBM's Deep Blue supercomputer and the early development of AI-driven market systems. His recent briefings focus on the intersection of AI, secrecy, and national acceleration. Media Contact:Derek WarrenPublic Relations ManagerParadigm Press GroupEmail: dwarren@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Yahoo

time9 hours ago

  • Yahoo

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025
PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Yahoo

time10 hours ago

  • Yahoo

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), ('PolyPid' or the 'Company'), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. Conference Call Dial-In & Webcast Information: Date: Monday, June 9, 2025 Time: 8:30 AM Eastern Time Conference Call: Webcast: About PolyPid PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid's proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid's lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit and follow us on Twitter and LinkedIn. Contacts:PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@ Investors:Brian RitchieLifeSci Advisors212-915-2578britchie@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store